This article is general information only. It does not take account of any individual’s health, medical history or circumstances, and it is not a substitute for advice from a general practitioner or an Accredited Exercise Physiologist. It sets out, in numbered clauses, what an exercise prescription is, what the national movement guideline for adults states, and how the four factors of the FITT principle relate to both.

1. What an exercise prescription is

An exercise prescription is a structured plan stating what exercise a person should do, how often, how hard and for how long, adjusted over time as the person’s capacity changes. Exercise and Sports Science Australia (ESSA) describes Accredited Exercise Physiologists as allied health professionals who specialise in prescribing tailored exercise programs for people with chronic conditions (media release, 2019).

The FITT principle describes the four settings of such a plan: frequency, intensity, time and type. The framework names what is set. It does not, by itself, state what the settings should be for any one person.

2. The national baseline

The Australian Government Department of Health, Disability and Ageing publishes 24-hour movement guidelines for adults aged 18 to 64. As stated on that page (accessed November 2026), the recommendations include:

1. moderate to vigorous physical activity for 30 minutes or more on most days;
2. muscle-strengthening activities on 2 or more days a week;
3. functional activities that target mobility, balance and coordination on 3 or more days a week; and
4. breaking up long periods of sitting.

The guideline is a baseline for adults in general. It is not a prescription, and it does not claim to be one. For a healthy adult it may serve as a reasonable starting point without further advice. Where a person has a health condition, an injury or takes medicine that bears on exercise, the guideline is a reference against which a professional assessment is made, not a substitute for it.

3. The FITT principle laid against the guideline

The table below is the writer’s own mapping of the guideline onto the four FITT factors. It is an analysis prepared for this article and is not a published table of the Department of Health. The third column restates the guideline as quoted above, and the fourth names, in qualified terms, what an individual assessment may change.

Two points follow from the table. The first is that the guideline gives figures for frequency and time but states intensity only in general terms (“moderate to vigorous”), so the intensity setting leaves the most room for interpretation for the person concerned. The second is that the last column carries the same qualification in every row, because any of the four factors may be altered by an individual’s circumstances and the guideline cannot say in advance which.

4. What an assessment looks at

An assessment by an appropriately qualified professional would ordinarily consider the person’s medical history, their current capacity and their goals. These inform the four settings and are reviewed as the person’s capacity changes. This article makes no claim about the results that any program produces, because the sources relied upon do not provide one.

5. Where to go

A person considering a program, particularly one with a health condition, may raise the matter with their general practitioner. An Accredited Exercise Physiologist is the professional ESSA identifies as prescribing tailored programs for chronic conditions. No provider is named or recommended here, and the choice of one remains a matter for the individual and their treating practitioner.

What applies, and to whom

The national guideline applies to adults aged 18 to 64 in general terms, and the FITT principle describes how any plan, general or personal, is constructed. A personal prescription differs from the guideline only in the settings, which are determined by assessment. This article is general information only, and the issuing authorities named below are the authoritative source on each point.

Sources: Australian Government Department of Health, Disability and Ageing, “Recommendations for adults (18 to 64 years)”, 24-hour movement guidelines (https://www.health.gov.au/topics/physical-activity-and-exercise/physical-activity-and-exercise-guidelines-for-all-australians/for-adults-18-to-64-years); Exercise and Sports Science Australia, “ESSA urges Australians to speak to the right exercise professional in 2019” (https://www.essa.org.au/Public/News_Room/Media_Releases1/2019/ESSA_urges_Australians_to_speak_to_the_right_exercise_professional_in_2019.aspx)

This article sets out what Australian clinical and public health sources say about the place of a gout diet in the management of gout. It is general information only; the reader’s own doctor, together with the documents cited at the foot, is the authority on every point made here.

The question considered is how much of the problem food can solve. The finding, stated at the outset, is that diet supports gout care but does not replace urate-lowering medicine. The popular instruction to cut purines and eat cherries is the position this article corrects, with qualification: the Australian sources do support some changes to food and drink, and they say so, but the Royal Australian College of General Practitioners (RACGP) states that diet alone “will almost never be sufficient to control gout”.

What national guidance says food can and cannot do

Three Australian documents are relied on throughout. The first is an article in the Australian Journal of General Practice, published by the RACGP in June 2018. The second is the Healthdirect page on gout, last reviewed in March 2026. The third is the Better Health Channel page on gout, reviewed on 11 November 2024. Where a statement below concerns a position taken in 2018, it is described as at 2018.

The subject is not a rare one. The RACGP article records that the prevalence of medically diagnosed gout in adult Australians “may be as high as 5.2%”, a figure published in 2018 and given there as an upper estimate, not a measurement. It is cited here for scale only: the question of what food can and cannot do concerns a considerable number of people.

The RACGP article lists the treatments indicated in the management of chronic gout as follows: education, diet and lifestyle changes, pharmacotherapy for acute flares, and long-term urate-lowering therapy. Diet is therefore part of the list, and the article does not dismiss it. A footnote then states the limit in a single sentence: “though some dietary modifications, such as increased consumption of milk/dairy and cherries, may be helpful, diet alone or the removal or addition of some foodstuffs will almost never be sufficient to control gout”. The article adds that, generally, “low-urate diets are not complied with”, and that diets compatible with optimal glycaemic control and primary cardiovascular prevention are usually acceptable.

Healthdirect takes a compatible position in different words. It records that there is “not much proof” that avoiding purine-rich foods reduces gout attacks, and it still advises a reader to avoid or limit foods that the reader has noticed may trigger an attack. It adds that most people find a healthy, balanced diet and keeping hydrated, together with medicine, is enough to manage their gout. The qualifier that matters is “together with medicine”.

The Better Health Channel, a Victorian Government service, states that gout can be successfully managed with healthy lifestyle choices and medical treatment, and that no special diet or “miracle food” can cure arthritis. Read together, the three documents say the same thing: food matters at the margin, medicine treats the cause of the problem, and no single food changes that order of importance.

The food and drink changes the Australian sources support

The table sets out each change that the three sources support, what the source says, and which source says it. It does not rank the changes in order of effect, because the sources do not.

The table excludes quantities. None of the three documents specifies how much of any food or drink is appropriate, and this article does not supply a figure of its own. It also contains no meal plan and no ranking of foods, because the sources offer neither. A reader who wishes to act on any row should ask the treating doctor what suits that reader’s circumstances.

Most of the rows are not specific to gout. Less alcohol, fewer sweet drinks, gradual weight loss and a balanced diet are changes that suit general health, and the RACGP notes that diets compatible with glycaemic control and cardiovascular prevention are usually acceptable. The rows about purine-rich foods, cherries and dairy are the ones the sources hedge most: “not much proof” in one case and “may be helpful” in the other.

Two rows call for a closer reading because they are the ones where the sources are most specific. On alcohol, Healthdirect names beer and spirits and advises avoiding binge drinking, while the Better Health Channel singles out beer. Healthdirect also lists beer among the yeast foods that are high in purines, so beer appears twice in its guidance, once as a drink and once as a purine source. On weight, both Healthdirect and the Better Health Channel advise gradual loss and warn against fad diets and crash dieting. The same advice is therefore both a recommendation and a caution: weight loss is supported, but the manner of losing it matters, and a rapid method may raise urate instead of lowering it.

Why a strict diet can still leave the flares

A reader who has followed a careful diet and still experiences attacks is not necessarily doing anything wrong, and the sources give four reasons.

1. The body produces urate itself. The Better Health Channel explains that uric acid arises when the body breaks down purines, which are “found in your body and in some foods”. Food is therefore one source of purines and not the only one. Healthdirect makes the same point from the treatment side, stating that the usual medicine lowers urate by reducing how much the body makes.
2. Several risk factors are not dietary. The RACGP lists increasing age, genetic factors, diabetes and diuretic use alongside purine-rich foods and alcohol. A person cannot adjust age or genetic factors by changing a menu.
3. The kidneys play a part. The Better Health Channel states that being overweight, having type 2 diabetes, or having high blood pressure or high cholesterol can leave the kidneys less able to flush urate out. This is a further reason why general health measures appear in the guidance alongside food.
4. Strict regimes can themselves raise urate. Healthdirect lists crash dieting or fasting among the factors that may raise risk, and the Better Health Channel states that crash diets can increase uric acid levels. A diet that is severe may therefore work against the person who adopts it.

The RACGP observation that low-urate diets are generally not complied with is relevant here as well. The sources do not suggest that the answer to continuing flares is greater strictness. They point to the treatment described in the next section.

What treats gout over the long term

The sources describe the long-term treatment of gout in a consistent sequence, set out in the clauses below. They contain no doses and no product names, which are matters for a prescriber.

1. The attack is treated first. The Better Health Channel states that the first step is to control the pain and inflammation of an attack.
2. Urate-lowering medicine is the long-term treatment. The RACGP lists long-term urate-lowering therapy among the treatments indicated for chronic gout, and the Better Health Channel states that a doctor may prescribe urate-lowering medicines, depending on how often attacks occur, the presence of tophi, kidney stones and other conditions.
3. Allopurinol is the first-line choice in the RACGP article (“Guidelines agree that allopurinol is a first-line urate-lowering therapy”) and the medicine most often used according to Healthdirect.
4. As at 2018, the RACGP article stated that febuxostat should not be used in Australia as first-line therapy, and that it was available on Pharmaceutical Benefits Scheme authority when allopurinol was contraindicated. The reader should check the current position with a doctor, because this statement is dated.
5. The RACGP article’s table of serum uric acid targets lists a general target of below 6 mg/dL (0.36 mmol/L) and, for severe or tophaceous disease, below 5 mg/dL (0.30 mmol/L). These are figures from the table as published in 2018. The target that applies to a particular person is set by that person’s doctor.
6. Monitoring is part of treatment. As at 2018, the RACGP article reported that fewer than 30 per cent of patients had serum uric acid monitored and that, of those, a third reached the target. The Better Health Channel adds that a blood urate test cannot of itself confirm gout, so a result is read by a doctor in context and not as a diagnosis.

The monitoring figure deserves emphasis because popular gout pages rarely mention it. Taken at face value, it says that in 2018 most patients were not having their urate measured, and that two thirds of those who were had not reached the target. It is a statement about practice at a point in time, and this article does not claim that it describes practice today. It does show why the treatment is described in terms of the urate level: that level is what the treatment is aimed at, so it has to be checked.

Reading overseas pages

Much of what appears in a search for a gout diet comes from outside Australia, and one trap deserves a separate mention. Pages from the United States commonly quote a urate target of below 6 mg/dL. Australian clinicians commonly work in millimoles per litre, and the RACGP table gives both units, with the same general target shown as 0.36 mmol/L. These are one figure in two units, not two different targets. A reader who meets 6 on one page and 0.36 on another has not found a conflict.

A second point is less technical. Overseas pages are written for other health systems, and they may differ from Australian guidance in emphasis and in the weight they give to food. It is prudent to check the country of any page before relying on it, and to treat the reader’s own doctor as the final authority on what applies in Australia.

Whichever units a page uses, the target it quotes is a general one. The RACGP table itself distinguishes a general target from a lower one for severe or tophaceous disease, and the individual figure remains the treating doctor’s to set.

What people say, and where it fits

Three positions recur in public discussion of gout and food, and the sources answer each of them.

The first is that a strict low-purine diet, with cherries, can control gout. The RACGP answers that cherries and dairy “may be helpful” but that diet alone will almost never be sufficient, and Healthdirect answers that there is not much proof that avoiding purine-rich foods reduces attacks.

The second is that years of careful eating failed and that medicine was what worked. This is consistent with the sources: the RACGP and Healthdirect both place urate-lowering medicine at the centre of long-term treatment.

The third is that a sudden, severe diet or fast preceded a first attack. This is consistent with the warnings in Healthdirect and the Better Health Channel about crash dieting and fasting.

There is a fair case for the diet-first view, and the sources support the part of it that is true. Alcohol, sweetened drinks, body weight and hydration all appear in the guidance, and a person who improves them is following it. The correction is one of proportion. Food changes help, and they help most when they accompany treatment and do not take its place. A reader who is reluctant to begin a daily medicine, and who hopes that a stricter diet will make it unnecessary, is asking food to do what the RACGP says it will almost never do alone. The sources do not address that reluctance directly, but the evidence they cite does not support relying on diet alone, and the person best placed to weigh it is the treating doctor.

Questions to take to your doctor

The sources point towards a short list of questions that a person with gout may wish to raise at a consultation. They are offered as a prompt and not as advice.

1. What is my urate level, and what is my target?
2. Would urate-lowering medicine suit me, and what would that involve?
3. When will my treatment be reviewed, and how will it be monitored?
4. Do my other medicines or conditions, such as diabetes or the use of diuretics, bear on my gout?
5. What should I do when an attack begins?

Medicine for the Urate, Food for the Rest

The position of the Australian sources can be stated in three clauses. Diet and lifestyle changes form part of gout care. Urate-lowering medicine treats the underlying urate level and is the long-term treatment. In the RACGP’s words, the removal or addition of some foodstuffs, and diet alone, “will almost never be sufficient to control gout”.

This article is general information only. The documents cited below are the authorities on the statements made, and a doctor is the authority on the treatment of any individual with gout.

Sources: Rogenmoser S and Arnold MH, Chronic gout: Barriers to effective management, Australian Journal of General Practice, volume 47, issue 6, June 2018 (https://www.racgp.org.au/AJGP/2018/June/Chronic-gout); Healthdirect, Gout, last reviewed March 2026 (https://www.healthdirect.gov.au/gout); Better Health Channel, Gout, reviewed 11 November 2024 (https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/gout)

This article sets out what Australian sources state about vitamin D deficiency, and in particular about who should be tested for it and who should not. It is general information only and is not a substitute for the advice of a general practitioner (GP). The authorities referred to throughout are the Royal Australian College of General Practitioners (RACGP), the Medicare Benefits Schedule (MBS), the Australian Bureau of Statistics (ABS) and the bodies that publish sun protection guidance.

Two statements are often placed side by side as though they conflict. The first is that vitamin D deficiency is common in Australia, particularly in winter. The second is that the RACGP does not recommend routine testing for it. Both are supported by the sources, and this article explains how they fit together. In summary, a population figure describes how many people have a low reading, while a testing criterion describes who is likely to benefit from a test. The two are different questions, and each is answered in a different document.

How common is vitamin D deficiency in Australia?

The most cited Australian measure comes from the ABS. Its article on vitamin D draws on the Australian Health Survey: Biomedical Results for Nutrients, 2011-12, and was released on 11 December 2013. The figures below describe 2011-12 and are reported as published.

1. About 23 per cent of adults, or about 4 million people, had a blood level of 25-hydroxyvitamin D below 50 nanomoles per litre (nmol/L).
2. The proportion differed by season: 36 per cent in winter, against 14 per cent in summer.
3. It also differed by age: 31 per cent of adults aged 18 to 34 years, against 15 per cent of those aged 65 to 74 years.

The ABS grouped low readings into bands. A reading of 30 to 49 nmol/L was classed as mild, 13 to 29 nmol/L as moderate and below 13 nmol/L as severe.

Two points follow from these figures. The first is that the seasonal gap is large, which is consistent with the common observation that winter is when low readings are most frequent. The second is that a figure of this kind is a statistic about a population. It is not a criterion for testing an individual. The finding that roughly one adult in four had a low reading in 2011-12 does not lead the RACGP to recommend that every adult be tested, as the sections below explain. The age pattern may also be unexpected: in this survey the proportion was higher among adults aged 18 to 34 years than among those aged 65 to 74 years.

What the cut-offs mean, and why documents differ

A reading has meaning only against a cut-off, and Australian documents do not all use the same set of bands.

The ABS and the RACGP each use 50 nmol/L as the line below which a reading is regarded as low. The ABS then divides low readings into mild, moderate and severe, as set out above. The RACGP guidance, in its resource titled First do no harm and revised on 1 November 2022, refers to 12.5 nmol/L in connection with short-term high-dose therapy, which is close to, but not identical with, the ABS boundary of 13 nmol/L for a severe reading. An older article in Australian Prescriber, published in 2010, used a different set of bands again, and no value is taken from it here.

The practical consequence is that a reported number should not be read from memory, or from a table on a web page. A result is read against the current guidance by the treating doctor, who will also consider the person’s circumstances and the reason the test was requested. For that reason this article provides no table for a reader to interpret a personal result.

A note on symptoms is also appropriate. Tiredness, aches and low mood are often mentioned in connection with low vitamin D. They are not specific to it, since each has many other causes, and a level can only be established by a blood test. A symptom alone is therefore not a reliable basis for concluding that vitamin D is low, or that it is adequate.

Who the Medicare rebate covers

The RACGP guidance, revised on 1 November 2022, states that vitamin D testing is “not routinely recommended for adults (including those who are pregnant), children or healthy infants”. It also states that testing funded by the MBS is limited to patients who meet listed criteria. Those criteria are set out in MBS item 66833, which sits in Category 6 (Pathology), Group P2. There are 11 of them, labelled (a) to (k). The item’s start date, description and fee were last updated on 1 November 2014.

Three clauses summarise the position as the sources state it.

1. The RACGP does not recommend routine testing of adults, children or healthy infants.
2. Testing outside the listed criteria is not among the situations that the MBS funds.
3. The wording of the criteria is for the treating GP to apply. One criterion, for example, refers to “chronic and severe lack of sun exposure for cultural, medical, occupational or residential reasons”. Whether a particular person’s circumstances fall within that wording is a clinical judgement, and this article does not suggest that any reader does or does not qualify.

The text of the 11 criteria is set out in the MBS itself. It is not reproduced here, because the schedule is the authoritative source, its wording is applied by the doctor, and the item may be amended. A reader who wishes to see the criteria should read item 66833 directly, or ask a GP to explain how it applies.

A rebate and a recommendation are easily confused. The question of who may have a test funded is answered by the MBS. The question of who should be tested is answered, for general practice, by the RACGP. The table below sets out what each source establishes, and what it leaves open.

What follows a low result

Treatment follows a doctor’s reading of a result and is not a matter for self-selection. The RACGP resource is nonetheless the document on which general practice relies, and its statements are set out below as published, with their date, for information only.

1. The RACGP guidance states cholecalciferol 25 to 50 micrograms (1,000 to 2,000 international units, IU) daily for adults with mild, uncomplicated deficiency.
2. The RACGP guidance states a target of about 10 to 20 nmol/L above the 50 nmol/L cut-off.
3. The RACGP guidance states that short-term high-dose therapy is not used routinely, and describes it in connection with a serum level below 12.5 nmol/L, higher body mass, or the advice of a specialist.
4. The RACGP guidance states that a result should not be retested within 3 months, and that the same laboratory should be used for the repeat. It also notes that the half-life of 25-hydroxyvitamin D is about 3 weeks.
5. The RACGP guidance states that supplementation is contraindicated in granulomatous disease, metastatic bone disease and sarcoidosis.

Each figure above is the RACGP’s, as revised in November 2022. None is a recommendation to a reader. A suitable amount for any person depends on the result, on other medicines taken, and on conditions such as those in clause 5, and for that reason it is a GP, and not a table, that settles it. The final clause also bears on supplements bought without a test. A person with one of the listed conditions would be affected by it whether or not a result had been obtained, and the point is a reason for speaking to a doctor before starting any supplement, not a reason for alarm.

Sun protection and vitamin D: how the two messages fit

A second source of hesitation is that the advice appears to point in two directions. Skin cancer prevention guidance asks Australians to protect their skin. Vitamin D, to the extent that the body makes it in the skin, depends on some exposure to sunlight. The sources cited here reconcile the two by treating them as questions about groups of people, and not as a single rule for everyone.

Neale and others published a revised position statement for Australian adults in the Australian and New Zealand Journal of Public Health in February 2024. Its abstract states that the balance of risks and benefits of sun exposure differs by person, and gives three examples.

The Cancer Institute NSW publishes guidance on sun exposure and vitamin D that is organised by skin type. For the general population, it advises protecting the skin when the UV Index is 3 or above. For skin types 1 to 4, it advises five forms of sun protection on days forecast to reach 3 or more, and advises against spending time outdoors deliberately in order to make vitamin D. For skin types 5 and 6, it advises spending enough time outdoors where possible, with no routine sunscreen unless the person is outdoors for a long period.

Read together, the two documents do not contradict one another. They describe different people. A person told to protect the skin, and a person told that routine sun protection is not recommended, have each been given advice suited to their own risks. Neither document is a licence to seek sun for its own sake, and neither states a number of minutes outdoors, so none is given here. Which group applies to a particular person is a matter for that person and a doctor, and not for a general article.

What people say, and what the guidance says

Three beliefs are common in public discussion of vitamin D. Each can be set against what the sources say.

1. That sunscreen and sun protection campaigns are the cause. The sources cited here do not link the survey figures to sunscreen use, so this article makes no claim either way. What the sources do state is that the balance of risk and benefit varies by skin type and risk, which is the reason for group-specific advice.
2. That winter days are short and many people work indoors. The ABS figures support the seasonal part of this belief, since 36 per cent of adults were below 50 nmol/L in winter against 14 per cent in summer. The ABS figures cited here are reported by season and age and not by occupation, but one MBS criterion refers to chronic and severe lack of sun exposure for occupational reasons, among others, so the concern is recognised in the schedule.
3. That it is better to be deficient than sunburnt. This presents a choice between two harms. The guidance does not frame it that way. It states that the balance differs by person, and it directs people at higher skin cancer risk to protect their skin, while describing a different position for deeply pigmented skin.

There is a fair point in the common concern that a person with a real risk factor should be able to ask for a test. The RACGP does not dispute that. The listed criteria exist for people in that position, and a person who believes that a criterion applies is entitled to raise it with a GP, who applies the wording.

Questions to take to a GP

A person considering a test or a supplement may wish to raise the following with a GP. The list is a prompt for discussion and not advice.

1. Does any risk factor that applies to me match a listed criterion for a funded test?
2. Have any symptoms persisted, and could they have another cause?
3. Which medicines and conditions do I have that bear on a test or a supplement?
4. What does a result mean against the current RACGP guidance, and which laboratory and units were used?
5. If a level is low, when should it be retested?

Points to Confirm With Your GP

This article has set out general information only. The RACGP is the authority on whether testing is recommended, the MBS is the authority on which tests are funded, and the ABS is the source of the survey figures. Each figure is attributed to its document and date, and none replaces a doctor’s reading of an individual result. A person with a question about vitamin D, a test or a supplement should confirm the position with a GP.

Sources: RACGP, First do no harm: Vitamin D testing, revised 1 November 2022 (https://www.racgp.org.au/clinical-resources/clinical-guidelines/first-do-no-harm/gp-resources/vitamin-d-testing); Medicare Benefits Schedule, item 66833 (https://www9.health.gov.au/mbs/fullDisplay.cfm?q=66833); Australian Bureau of Statistics, Vitamin D, from the Australian Health Survey 2011-12, released 11 December 2013 (https://www.abs.gov.au/articles/vitamin-d); Neale and others, Balancing the risks and benefits of sun exposure, Australian and New Zealand Journal of Public Health, February 2024 (https://research.bond.edu.au/en/publications/balancing-the-risks-and-benefits-of-sun-exposure-a-revised-positi/); Cancer Institute NSW, Sun exposure and vitamin D (https://www.cancer.nsw.gov.au/prevention-and-screening/preventing-cancer/preventing-skin-cancer/reduce-your-skin-cancer-risk/sun-exposure-and-vitamin-d)